MicroDose Therapeutx and Moerae Matrix have agreed to collaborate on development of a dry powder inhaler, using MicroDose DPI technology to deliver Moerae’s MMI-0100 MK2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF). There are no treatments for IPF currently approved in the US. According to the companies, "MMI-0100 is a selective inhibitor of … [Read more...] about MicroDose Therapeutx and Moerae Matrix to collaborate on inhaled MK2 inhibitor
News
Judge rules for Apotex in Merck’s Nasonex patent infringement suit
According to Bloomberg News, Merck plans to appeal a ruling by Judge Peter Sheridan of the US District Court for the District of New Jersey that Merck failed to prove its allegation that Apotex infringed on its Nasonex patent. At the same time, the judge upheld the validity of the patent, which Apotex had challenged. Apotex filed an ANDA for mometasone nasal … [Read more...] about Judge rules for Apotex in Merck’s Nasonex patent infringement suit
Rigel licenses inhaled JAK inhibitor to AstraZeneca
Rigel Pharmaceuticals has granted AstraZeneca an exclusive worldwide license for development and commercialization of its R256 inhaled JAK inhibitor for the treatment for moderate to severe asthma. The deal includes an upfront payment of $1 million with a potential $8.25 million in milestone payments by the end of next year; according to the two companies, the total … [Read more...] about Rigel licenses inhaled JAK inhibitor to AstraZeneca
Analyst predicts slight increase in asthma and COPD drug market over next five years
A new report from Transparency Market Research titled "Asthma and COPD Drug Market - Global Industry Analysis, Market Size, Share, Trends, Growth and Forecasts, 2010 - 2017" predicts an increase in the asthma and COPD drug market from ~25 billion in 2010 to ~27 billion in 2017. The report suggests that price erosion and the expiration of patents with few novel drugs … [Read more...] about Analyst predicts slight increase in asthma and COPD drug market over next five years
Civitas initiates Phase 2a study of inhaled L-dopa
Civitas Therapeutics has announced the initiation of a Phase 2a clinical trial of its CVT-301 inhaled L-dopa for the treatment of motor fluctuations in patients with Parkinson’s disease. CVT-301 is formulated and delivered using the company's proprietary Arcus dry powder technology. Development of the product is being funded in part by the Michael J. Fox Foundation … [Read more...] about Civitas initiates Phase 2a study of inhaled L-dopa
Impel NeuroPharma announces advances in development of pressurized olfactory device
Impel NeuroPharma says that a study has shown that its Pressurized Olfactory Device (POD) was preferred 2 to 1 by testers compared to conventional nasal sprays. POD delivers aerosolized drug, both liquid and powder formulations, to the upper nasal cavity, allowing delivery of therapeutics across the blood-brain barrier, according to Impel. The company says that it … [Read more...] about Impel NeuroPharma announces advances in development of pressurized olfactory device
Bespak MDI valve sales up 12%
Consort Medical has announced record revenue and profits for the year ending April 30, 2012, including a 12% increase in revenue for its Bespak division, which manufactures metered dose inhaler valves and actuators as well as dry powder inhalers. Bespak's operating profit also grew by 17%. According to Consort, the growth in Bespak revenue came about in part due to … [Read more...] about Bespak MDI valve sales up 12%
Savara announces Phase I study results for AeroVanc, funding for Phase 2
Savara Pharmaceuticals has announced positive top-line results from a Phase 1 study of its AeroVanc inhaled dry powder formulation of vancomycin for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis. According to the company, the study demonstrated that AeroVanc was well tolerated, that clearance of the … [Read more...] about Savara announces Phase I study results for AeroVanc, funding for Phase 2
Pharmaxis submits NDA for Bronchitol, issues update on commercialization in Europe
Pharmaxis has submitted an NDA for Bronchitol inhaled dry powder mannitol for the treatment of cystic fibrosis to the FDA. Pharmaxis CEO Dr Alan Robertson said, “The submission marks the second of two key milestones for the Bronchitol program following approval last month to market the product in Europe. Cystic fibrosis patients have a life‐limiting disease. It … [Read more...] about Pharmaxis submits NDA for Bronchitol, issues update on commercialization in Europe
Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study
Alnylam Pharmaceuticals says that its ALN-RSV01 inhaled RNAi drug failed to meet the primary endpoint of a Phase 2b study, not significantly reducing the incidence of bronchiolitis obliterans syndrome (BOS) at 180 days after infection in lung transplant patients infected with respiratory syncytial virus (RSV) in an “intent-to-treat” (ITTc) analysis, but that it met … [Read more...] about Alnylam inhaled RSV drug misses primary endpoint in Phase 2b study